Home Medicine Pharmacodynamic Monitoring of Mycophenolate Mofetil
Article
Licensed
Unlicensed Requires Authentication

Pharmacodynamic Monitoring of Mycophenolate Mofetil

  • Klemens Budde , Petra Glander , Steffen Bauer , Kay Braun , Johannes Waiser , Lutz Fritsche , Ingrid Mai , Ivar Roots and Hans-Hellmut Neumayer
Published/Copyright: November 12, 2000
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 38 Issue 11

Abstract

The immunosuppressive activity of Mycophenolate Mofetil (MMF) is based on the reversible inhibition of inosine-5′-monophosphate dehydrogenase (IMPDH) by mycophenolic acid. Pharmacodynamic monitoring by measurement of IMPDH activity reflects directly the biological response to MMF. For measurement of IMPDH activity in peripheral mononuclear cells we established a modified non-radioactive procedure, based on the incubation of cell lysates with inosine-5′-monophosphate and the chromatographic quantification of produced xanthosine-5′-monophosphate by isocratic ion-pair reversed phase HPLC. The between-run precision and within-run precision were 7% and 5%, respectively. We determined the time course of IMPDH activity in five patients after 1g MMF and in five healthy subjects without administration of MMF. Additionally, IMPDH activity was determined in a population study of 40 healthy volunteers. In healthy volunteers, we observed a wide range of IMPDH activity (4.7–32.9 nmol/h/mg) with only weak diurnal variation. All patients receiving MMF had a significant reduction of IMPDH activity (65–100%) after administration of the drug. Inhibition persisted for up to 6 hours, and after 11 hours IMPDH activity returned to predose activities. The interindividual variability of IMPDH activity may account for pharmacodynamic differences in MMF-treated patients. Based on pharmacodynamic monitoring better dosing strategies for MMF-treated patients may evolve.

:
Published Online: 2000-11-12
Published in Print: 2000-11-12

Copyright © 2000 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. European Meeting on Biomarkers of Organ Damage and Dysfunction Selected Papers from the Meeting Held in Cambridge, UK April 3rd-7th, 2000
  2. Kidney Retrieval Conditions Influence Damage to Renal Medulla: Evaluation by Proton Nuclear Magnetic Resonance (NMR) Spectroscopy
  3. Citrate, Acetate and Renal Medullary Osmolyte Excretion in Urine as Predictor of Renal Changes after Cold Ischaemia and Transplantation
  4. Comparison of Proteolytic Enzymes and Glutathione S-Transferase Levels in Non-Heart-Beating Donors' (NHBD) Kidney Perfusates
  5. Assessment of Non-Heart-Beating Donor (NHBD) Kidneys for Viability on Machine Perfusion
  6. Low Levels of Urinary Albumin Excretion Are Associated with Cardiovascular Risk Factors in the General Population
  7. Evaluation of a Fully Automated Assay to Measure C-Telopeptide of Type I Collagen in Serum
  8. Bone Turnover Markers and Estradiol Level in Postmenopausal Women
  9. External Quality Assessment of Bone Metabolism Marker Assays. Initial Experiences in a UK NEQAS Programme
  10. The Monoethylglycinexylidide (MEGX) Test as a Marker of Hepatic Dysfunction in Septic Patients with Pneumonia
  11. Transforming Growth Factor-β1 as a Surrogate Marker of Hepatic Dysfunction in Chronic Liver Diseases
  12. A New Approach to the Evaluation of Liver Graft Function by Nuclear Magnetic Resonance Spectroscopy. A Comparative Study between Euro-Collins and University of Wisconsin Solutions
  13. Metallothionein and Heat Shock Protein Expression during Acute Liver Injury and Regeneration in Rats
  14. Biochemical Evaluation of Patients with Acute Pancreatitis
  15. Screening for Acute Myocardial Injury: Creatine Kinase Is Comparable to Myoglobin
  16. Different Time Frames for the Occurrence of Elevated Levels of Cardiac Troponin T and C-Reactive Protein in Patients with Acute Myocardial Infarction
  17. Determination of Decision Limits for ACS:Systems Cardiac Troponin I
  18. Stability of Cardiac Troponins and CK-MB Mass Isoenzyme
  19. Cytokines as Plasma Markers of Abdominal Aortic Aneurysm
  20. The Early Fall in Levels of S-100 β in Traumatic Brain Injury
  21. Protein S-100β in Brain and Serum after Deep Hypothermic Circulatory Arrest in Rabbits: Relationship to Perivascular Astrocytic Swelling
  22. The Effect of Continuous Treatment with Sodium Nitroprusside on the Serum Kinetics of the Brain Marker Protein S-100β in Neonates Undergoing Corrective Cardiac Surgery by Means of Hypothermic Cardiopulmonary Bypass
  23. Differentiated Therapy with Prostaglandin E1 (Alprostadil) after Orthotopic Liver Transplantation: the Usefulness of Procalcitonin (PCT) and Hepatic Artery Resistive Index (RI) for the Evaluation of Early Graft Function and Clinical Course
  24. The Postoperative Course of γ-Glutamyl Transpeptidase – a Marker of Cytomegalovirus (CMV) Replication Risk?
  25. TNF-α and Its Receptors Mediate Graft Rejection and Loss after Liver Transplantation
  26. Impact of Ig-Therasorb® Immunoapheresis on Stability of Xenogeneic Ex Vivo Porcine Liver Perfusion – Value of Aminotransferases and Flow Rates for the Assessment of Metabolic Graft Viability
  27. The Effect of Human Organ Preservation and Albumin Flush Solution on In Vitro Cell Metabolic Activity
  28. An Ex Vivo Model of Tolerance vs. Rejection: Comparison of Different Signal Transducers and Activators of Transcription, STAT1, STAT4, STAT5 and STAT6
  29. Detection of Cytomegalovirus (CMV) Antigens in Kidney Biopsies and Transplant Nephrectomies as a Marker for Renal Graft Dysfunction
  30. Comparison of Five Cyclosporin Immunoassays with HPLC
  31. In Vitro Pentamer Formation as a Biomarker of Tacrolimus-Related Immunosuppressive Activity after Liver Transplantation
  32. Pharmacodynamic Monitoring of Mycophenolate Mofetil
Downloaded on 21.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2000.191/html
Scroll to top button